在外教育施設派遣教員安全対策資料 在外教育施設派遣教員安全対策資料
|
|
|
- るるみ ごちょう
- 5 years ago
- Views:
Transcription
1
2
3
4
5
6 ORS ARI
7 SARS SARS SARS SARS SARS SARS SARS SARS BCG DPT Hib BCG
8 Emerging/Re-emerging Infectious Diseases
9 (1)
10 (2) (3) (4)
11 X
12
13 X 1. 3.
14
15 5
16 6
17
18 8 BCG DPT BCG WHO BCG 1957
19 9 Hib (2)
20
21
22
23
24
25
26
27 17
28
29
30
31 General Practitioner Family Medicine Internal Medicine Pediatrics
32
33
34
35
36 26
37 27 PTSD
38
39 WHO
40 ,
41 HIV/AIDS
42
43
44 SARS PTSD
45 PTSD PTSD
46 36 SARS 5. 1.
47 37 O-157 (3) 5. 2.
48
49 39 1
50 5. 3. Oral Rehydration Therapy WHO UNICEF 1975 Oral Rehydration Salts/Solution, ORS ORS ORS OS-1 40
51 ORS ORS Na (mmol/l) K (mmol/l) (g/l) ORS (WHO) OS ORS 41
52 ARI Acute Respiratory Infection, ARI
53
54
55 45
56 46
57
58 ,
59 1. No.4027, p Travel Health Onlinehttp:// 3. CDC: Modern Physician Red Book 2003, 26 th ed.american Academy of Pediatrics
60 50 6 HIV/AIDS WHO
61 (Plasmodium falciparum) (P. vivax) (P. malariae) (P. ovale)
62 DIC
63
64 WHO WHO 28 72
65 25mg 500mg Stevens-Johnson 1 qinghaosu G6PD 55
66
67
68
69 59
70 SARS SARS Knowledge dispels fear SARS SARS Severe Acute Respiratory Syndrome SARS SARS SARS SARS SARS SARS SARS 60
71 SARS SARS 2004 SARS SARS SARS Basic Reproductive rate; R SARS ARDS SARS 12 SARS SARS 61
72 CT SARS APTT LDH SARS PCR SARS SARS SARS Isolation Contact Tracing Quarantine SARS
73 SARS WHO SARS WHO WHO Global Epidemic Surveillance SARS WHO WHO SARS WHO (3) SARS SARS SARS Respiratory etiquette SARS 63
74 7.5.3.SARS SARS SARS SARS SARS SARS SARS 7080 SARS SARS Personal Protective EquipmentPPE 64
75 WHO UNICEF EPIExpanded Programme on Immunization BCG DPT
76 BCG BCG 66
77 BCG BCG BCG BCG WHO UNICEF 1, WHO DPT 67
78 8.3.3.DPT 1990 DPT Hib DPT DT DPT 1970 DPT 1981 DPT DPT
79 MMR MMR MMR Jeryl-Lynn MMR 1975 MMR MMR MMR 1989 AIK-C TO336 Am MMR MMR MMR
80 WHO WHO International Health Regulation 70
81 WHO WHO Hib 71
82 Hib WHO BCG BCG BCG
83 MMR MMR
84 MMR WHO DPT DT 1968 DPT 12 DT
85 Ty21a V
86 FORTH 2,000 (3) WHO
87 BCG DPT B Hib * **Hib HibDPTHibDPT HibDPT 77
88 Hib International Travel and Health (WHO,Geneva,1999) 1997 Red Book, American Academy of Pediatrics p5 Hib HibDPTHibDPT HibDPT 78
89 (*) (*) 79
90 80
91 communicable disease infectious disease 81
92 9. 3. Emerging/Re-emerging Infectious Diseases 1995 WHO emerging and re-emerging infectious diseases emerging infectious disease re-emerging infectious diseases
93 (1999 )
94 (2001 ) (2003 ) WHO Global Alert (SARS: Severe Acute Respiratory Syndrome) SARS SARS
95 SARS
96 SARS SARS A VRSA
97 RS SARS SARS WHO 87
98 , , (CD-ROM ) ( (Infectious Disease Weekly Report: IDWR) SARS IDWR ( IDWR PDF 88
99 HTML CD-ROM 89
100 90
101 91
102 92
103 SARS E A Q B E A AIDS/HIV RS A 93
104 94
105
106
107 97
108
109 A A B C
110
111 101 N95 dust-mist:dm dust-fume-mist:dfm ml
112
113
114
115 (1) ISBN , ISBN ,
116 4 410 ISBN , ISBN X1, ISBN , ISBN , ,447 NIS
117 230 1, (2) 135 ISBN , ISBN , ISBN ,
118 1,672 ISBN , ISBN , ISBN ,
119 320 3, ( A (3) (JICA) 20 ODA
120 (JOHAC) FAX (JOMF) SARS JOMF-
121 WHO International Travel and Health 2001 Travel Health Online Shoreland, Inc CDC Travelers Health CDC Diseases 111
122 Traveling with children WHO International travel and health WHO FAX
123 (4) JOHAC 113
124 114 FAX JOHAC JOHAC
125 T-PORT JOHAC JCB JCB
126 JCB JCB 1 24 JCB 16 JCB
127 SARS
JOMF-ｷｯｽﾞﾈｯﾄQ&Aﾌﾞｯｸ
Q&A Q&A A B Hib Hib DPT A MMR A MMR M measles M mumps R rubella MMR MMR MMR MMR MMR A BCG BCG BCG BCG BCG BCG BCG BCG BCG BCG BCG BCG BCG A A WHO A A B C D E A B A B B s DPT B B B A Vi A A O A
加藤茂孝先生
ooooooo oooooooooooooooooooooooooo 10 30 11 oooooooooooooooooooooooooo Shigetaka KATOW ooooooo 1 1 1 100 1 1 3 2003 SARS SARS 9.11 2 2 30 2003 SARS 2009 200 SARS 1 2001 0101-0051 - RIKEN Center of Research
-51-
-50- -51- 11 3 28 8 1 24 7 2 36 10 1-52- -53- 1 2-54- 6 1 2 3 4 5 6 6 1 19 5 200 300ml 20 6 400ml -55- -56- 10-57- 4 2 20-58- 2,500-59- -60- -61- 2-62- 6 3-63- 9 68 1 6-64- 3-65- 4-66- 5 6-67- -68- 1 1
フィナレビ106号.indb
2009 3 30 2009 4 14 CDC 2009 4 25 WHO 2009 4 26 2009 4 28 2009 4 28 2009 4 30 2009 5 1 2009 5 8 6 2009 5 9 2009 5 23 2009 6 3 2009 6 9 2500 2009 6 12 WHO 6 2009 6 28 2009 8 9 1 1 2009 8 15 2009 8 19 2010
idwr2008_21
VanC 521 0.63 0.24 2.12 2.27 1.07 0.98 1.75 0.70 27.24 0.76 1.16 0.35 1.26 0.71 2SD 1SD 1SD 2SD A SD 0.21 0.58 3.02 7.02 1.89 0.70 0.20 0.72 0.11 0.37 0.43 0.04 0.79 0.39 5515 6.19 Streptococcus pyogenes
(Travel Medicine) (Emerging Re-emerging Diseases) ) ) ) ) ) ) ) 10 ) 12 ) ) 12 ) 13 ) 14 ) 15 ) 17 ) 18 ) 20 ) 22 24
1999.No2(22) (Travel Medicine) (Emerging Re-emerging Diseases) ) ) ) ) ) ) ) 10 ) 12 ) ) 12 ) 13 ) 14 ) 15 ) 17 ) 18 ) 20 ) 22 24 Travel Medicine Travel Clinic i) ii) iii) ) 200 Emerging Re-emerging Diseases
諸外国における妊娠・出産等に関する情報提供事例収集 2
樽 1. WHO 2012World Health Statistics 2012 32 2.1 Centers for Disease Control and Prevention; CDC 33 20091544 1,000 102.1 12302 636 9413 1115 2108 7 1990200930 30 30 19755 201026 34,35 12 1990,2000,2009CDC/NCHS
13●53頁●６－７▲院内感染対策▲.ppt
No.610 1 No.121 2 No.128 Nosocomial infection, Hospital-acquired infection CDC nosocomial infection, hospital-acquired infection nosocomial nosokomeion hospital nosocomial infection nosocomial pneumonia
:,, : - 7 -
31 ~ ~ - 6 - :,, : - 7 - (),,,,,,; ~ ~ *1 *2 6,,,~,,~ - 8-32 ,, ( );( ),,,,,, ~ ~ ~,,,, (),,,,, - 9 - 33 ~*~ ~~ ~, ~ ~ ~ ~ ~, ~~,,,, - 10 - BCG () g ) BCG BCG,, 34 ,,,, (),,,,,,,,,,,,,, () ( 3 90 [7 6
37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
Microsoft Word - 講演録.docx
2015.9.7 70 21 11 3 22 5 3 14 1 1 1 2 3 2 2 12 7 3 6 1 7 11 2 3 4 1 1 3 11 (1) (2) (2) 5 2 ( ) 6 15 6 6 2 0 PTSD PTSD PTSD 5 50 7 240 17 3 31 560 PTSD 560 500 500 8 40 9 2 11 1 1 750 700 PTSD 350 10 1
10 1-1 - 30 2-2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - 18-9 - - 10 - PTSD 100-11 - - 12 - - 13 - 17 // - 14 - 27 151-15 - - 16 - - 17 - - 18 - - 19 - - 20 - E - 21 - - 22 - - 23 - - 24 - - 25 - 28 4-26
untitled
c OR 21 OR 1. 21 21 IoT OR OR OR 260 8672 1 8 1 OR 2. 2.1 public health [1] communicable (infectious) diseases vehicle burden HIV/AIDS (SARS) 258 60 Copyright c by ORSJ. Unauthorized reproduction of this
untitled
WHO 20 SARS (World Health Organization WHO) Strategic and technical meeting on intensified control of neglected tropical diseases: A renewed effort to combat entrenched communicable diseases of the poor
1 105 2 4 50 3 ISBN 4 25 2013 1 ISBN 5 128p ISBN978-4-8340-0013-9 ISBN 2
1 2 39 3 14 13 16 17 36 21 30 32 1 1 105 2 4 50 3 ISBN 4 25 2013 1 ISBN 5 128p ISBN978-4-8340-0013-9 ISBN 2 39 32p ISBN978-4-251-00517-5 62p ISBN978-4-00-110579-7 1 33p ISBN978-4-477-01141-7 3 32p ISBN978-4-591-01270-3
496
495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 ISBN4-258-17041-0
() () () () ( ) () () () () () () () () () () () () () () () () () () () () () () ( () () () () () () () () () () () () ) () ( ) () () ( ) () () () () () () () () () () () () () () () () () () () ()()
ISBN 0 00 00 00 0 0 ISBN 0 0 ISBN---.000-0
ISBN 0 00 00 00 0 0 ISBN 0 0 ISBN---.000-0 0 ISBN 0 00 00 00 0 0 ISBN 0 0 ISBN---.000-0 ISBN 0 00 00 00 0 0 ISBN 0 0 ISBN---.000-0 ISBN 0 00 00 00 0 0 ISBN 0 0 ISBN---.000-0 ISBN 0 00 00 00 0 0 ISBN 0
0 00 000 000 ISBN 0 0 0 ISBN 0 0 0 ISBN---.00-
0 0 0 --- -0--0-- 00 0 00-0 0 0 0 0 000-00- 0 00 000 000 ISBN 0 0 0 ISBN 0 0 0 ISBN---.00- 0 00 000 000 ISBN 0 0 0 ISBN 0 0 0 ISBN---.00- ISBN 0 0 0 ISBN 0 0 0 0 00 000 000 ISBN---.00- 0 00 000 000 ISBN
(()) () ( ) () () () () () () ( ) () () () () () () () () () () () () ( ) () ( ) () () () ( ) () () () () () ( ) () () () () ( ) () ( ) () () ( ) () ( ) () () () () () () () () () () () () () () () ()
idwr2015_24
S. boydii S. sonnei K. pneumoniae E. aerogenes E. coli E. cloacae E. aerogenes K. pneumoniae 5 2.40 0.19 0.76 1. 1. 0.34 0.61 0.51 0.62 0.37 0.45 1.49 2SD 1SD 1SD 2SD A SD 0.17 0.77 55 1.22 4. 3.64 7.
untitled
18 12 10 40 H5N1 2005 11 WHO 2005 12 2006 6 (H5N1) 10 25 1,700 ( 1,300 2,500 ) 200 53 64 17 30% 3,785,000 291,200 3 14,100 4 30% 57,600 4,430 3 1,150 320 210 4 2% 0.56% () ) 1 10 2 3A (2B) 3B 4A5A 6A 4B
加藤茂孝先生
Shigetaka KATOW 2009 4 24 WHO 5 9 1 5 16 1 TV 6 12 6 11 WHO 6 4 5 12 E-mail : modern_media@eiken.co.jp 2009. 4. 28. http:idsc.nih.go.jpidwrkanjaweeklygraph01flu.html 0101-0051 - RIKEN Center of Research
DNA
1 1 1. 1 2. 2 3. 2 4. 2 2 1. 2 4 5 7 2. 7 3. DNA 8 4. 10 13 Plasmodium (P. falciparum) (P. vivax) (P. malariae) P. ovale 4 40% 200 7 40 48 72 1. - 1 - 2. DNA 3 3. 1) 2) 3) 4) 4. 1 1) - 2 - 2) EDTA 1) 1
EMS EMS W264
ILCOR-CoSTR 10 Part 10 First Aid (2/5) (introduction) (definition of first aid) (medical emergencies) (injury emergencies) (environmental injuries) 2004 AHA ARC National First Aid Science Advisory Board
スライド 1
不活化ポリオワクチンの円滑な導入に関する検討会 第 2 回会議 諸外国の OPV から IPV への 移行時の対応等 2011 年 10 月 14 日 ( 金 ) 中野貴司 ( 川崎医科大学小児科 ) 米国における OPV IPV の移行 1.1997 年 1 月より IPV/OPV sequential( 併用 ) スケジュール IPV を 2 ヵ月,4 ヵ月の 2 回 OPV を 6-18 ヵ月,4-6
4 1 2 93 1889 22 4 7 1955 303 1869 2 5 3 188 8 7 5 4 5 22 51 16 1619 5 4 5 1843 14 6 28 12 15,000 1621 7 1 2 7 4 7,520 10 2010 223 29 19 2 1897 30 4 8 1786 6 1846 3 1817 14 9 1793 5 1862 2 10 1818 22 17
座談会/2009
6 2008 10 3 9 2008 2 9 Asian-African Research Network 4 A preliminary experiment of Japan over these four years05 08 1900 2000 50 3 50 3 1969 Surgeon General William T. Stewart 2003 SARS SARS 2003 2 M
橡アロマセラピー症状別処方例.PDF
1 1 92 E 100ml 1 2 2 1 93 0.5m 10ml 100ml 1 2 3 2 52 0. l 2 4 3 27 3 1 1 3 3 4 5 3 2g 2 3 1 1 1 10ml 3 4 6 3 29 2 2 2 10ml 3 3 4 7 3 30 2 1 2 10ml 3 3 4 8 3 31 1 1 1 1 3 60 10 10 3 2 4 10ml A 2 3 61 20
Cover_Page.qxd
Michael Foley JSDF5 JSDF JSDF JSDF 20052004 12 26 2000 2005 JSDF JSDF 1 JSDF JSDF NGO JSDF JSDF JSDF Preah Vihear JSDF 2002 iii 2004 70 JSDF 2004 12 26 JSDF 2005 8 2005 7JSDF JSDF 2006 JSDF JSDF 2 7400
104 100 60 9,195,336 409 0.004 24 8 31 9,025,983 568 0.006 2012 8 31 6,634,686 956 ( 0.014 ) 2 2011 8 26
25 25 3 5 MMR 1 104 100 60 9,195,336 409 0.004 24 8 31 9,025,983 568 0.006 2012 8 31 6,634,686 956 ( 0.014 ) 2 2011 8 26 2012 8 31 1,032,660 132 ( 0.013 ) 3 2010 6 11 3 11 15.4 1 1 ( ) 12 2 2 3 ER ) (
2014Vol.63No.4p.342349 New impediment factor to health: biological contamination U YANAGI School of Architecture, Kogakuin University Abstract More than 40 years have passed since the Act on Maintenance
熱中症－２.PDF
Vol.14,No 56 Aug.2005 Vol.14 No.4 1960 27 65 1 60% 40% 7080% 50% 40% 15% 5% 2 Vol.14,No. 40% 15% 5% 142 144 15 4 4 150 5 2.5 2 3 1.5 27 154 152 194 103 114 1 27 30 10 2 2 100 1 1 20 5 5 16 0 63 154 152
Summary
Summary Itiswell-knownthatpeopleare infected with malariavia mosquitos called Anopheles spp. The present paper describes the distribution of malaria on earth, historyofthedisease, biology, lifecycle, syndrome,
ジカ熱の広がり2005 2014 Zika virus: following the path of dengue and chikungunya? globally, similar to dengue (DENV) time and caused an epidemic on Yap Island in the Federated States of and chikungunya (CHIKV)
(%) 6. 5. 4. 3. 2. 1.. -1. -2. -3. -4. -5. 21/1-3 22/1-3 23/1-3 24/1-3 18, 17, 16, 15, 1 92 84 76 14, 68 13, 6 12, 52 11, 44 1, 9, 8, 7, 36 28 2 22/1 22/7 23/1 23/7 ( 1 FACT BOOK 24 2 14, 12, 1, 8, 6,
小児感染免疫第29巻第2号
小児感染免疫 Vol. 29 No. 2 153 症例報告 1 1 1 1 1 1 11 2 15C 14 17 細菌性髄膜炎は, 肺炎球菌, インフルエンザ菌 b 型ワクチン導入により減少傾向であるが, 現在でも予後不良な疾患である. 先天性内耳奇形では, 細菌性髄膜炎を発症することがあることが知られているが 1,2), 細菌性髄膜炎を発症したワクチン未接種の先天性内耳奇形の 1 例を経験したため報告する.
2001 2003 2005 2006 2007 2008
2001 2003 2005 2006 2007 2008 60 etc. http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm 23.5% 2.8% 2.8% 3.4% 30.3% 9.9% 11.5% 15.8% AAN 65
8
7 8 9 1 1-1 1-2 2002 1 2000 10 1-3 2002 2 2000 11 2 3 WHO19951979 19952002p.47 4 22 5 12 2-1 18681919 6 1965 13 2-2 19201945 14 15 2-3 19461960 7 16 17 2-4 19611979 GDP 18 1956300 2,000 1960 11 1972 231006
受益証券発行信託受益権の 株式等振替制度対応に関する説明会
apanese Depositary Receipt Copyright 2010 Tokyo Stock Exchange, Inc. 1 Copyright 2010 Tokyo Stock Exchange, Inc. 2 American Depositary Receipt Global Depositary Receipt Copyright 2010 Tokyo Stock Exchange,
SARS HIV/AIDS n = 672; % 5% 2% 8% 16% 43% 20%
SARS HIV/AIDS n = 672; 20074 20108 6% 5% 2% 8% 16% 43% 20% 1999 2008 HIV/AIDS B A 0% 50% 100% 1049 552 17 186 867 431 739 3847 332 7556 102 2420 3648 449 802 2709 31774 1286 13651 1611 207 95 8 162 667
24回日本エイズ学会誌1_ indd
10 ICAAP 11 24 9:40 10:10 1 B1F 1. 10 Myung-Hwan Cho 2. Zahid Hussein President of AIDS Society of Asia and the Pacific ASAP 11 24 13:10 15:40 1 B1F 1 13:10 13:55 PS1-1 ART in the Developing World: Progress
01
2 0 0 7 0 3 2 2 i n d e x 0 7. 0 2. 0 3. 0 4. 0 8. 0 9. 1 0. 1 1. 0 5. 1 2. 1 3. 1 4. 1 5. 1 6. 1 7. 1 8. 1 9. 2 0. 2 1. 2 3. 2 4. 2 5. 2 6. O k h o t s k H a m a n a s u B e e f 0 2 http://clione-beef.n43.jp
untitled
6 ( ). 1.. 1. 2. 3. 4. 5. ( ) 6. 7. 8. . 1. 1) 1 (12 3 ) 2 2) 3) ( ) ( ) 4) 2 () 2 2 3 5) ( ) R-Book ATLAS () 8 12 7 18 14 16 10 21 14 23 16 18 16 18 12 25 4 14 21 1 4 2 3 4 4 1 2 7 5 1 2 5 7 9 1 1 5 5
Microsoft Word - 表紙資料２－４
(1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)
1 1.1 ワクチンの定義 Variolae vaccinae 1798 1 1. A B b Hib 2 1 4 2012 1. 2012 5 2. 1 1 13 bb 3 B b 3. 6 2012 1 3 23 1.2 4 3 A B DTaP Tdap bhib 2 HPV H1N1 3. 2 AS04 A MF59 2 2. 1... http://www.fda.gov/biologicsbloodvaccines/safetyavailability/vaccinesafety/ucm096228#t2
1965( 40) * 1969( 44) 1996( 8) 5 * 1995( 7) 10 10 1997( 9) 10 1996( 8) 12 5 2000( 12) 12 2002 14 3
1 20 1948( 23) 12 10 3 ( )* 1993( 5) 1994( 6) 1995( 7) 2004( 16) 10 10 10 * 1965( 40) * 1969( 44) 1996( 8) 5 * 1995( 7) 10 10 1997( 9) 10 1996( 8) 12 5 2000( 12) 12 2002 14 3 * 2003 15 10 2 HIV* * 1997(
日医雑誌第126巻第9号
[] HIV 4 sexually transmitted diseases 1975 WHO 12 3 2 5 3 1 1 4 3 40 1 1947 4 WHO 1975 STDsexually transmitted diseases STIsexually transmitted infection 5 STD 5 10 20 5 5 HIV STD RTIreproductive tract
Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS BPD CHD 50mg100mg RS20138 RS Respiratory Syncytial Virus RS
RS Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS1998 7020021BPD 200510CHD 50mg100mg2012 812 RS20138 RS Respiratory Syncytial Virus RS 28 12 29 35 6 6BPD24 24CHD 24 24 28 2935 RS 12 6 RS BPD
地域と文化資産
11 2005 1980 151 20 65 1 6 37 7 A D E F G H - 2 - 2005 8 6 10:00 10:30 2-432 A D 7 E 8 1-F 1-G - 3 - 2005 H 1970 2005 8 26-4 - A B D E F G H 3 7 8 1 5 6 1 10-5 - 2005 10 1 5 6 1 1 30 2 3 5 3 2 1 2005 8
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 http://www.moj.go.jp/press/090130-1.html 55 56 57
NETWORKER s s 2 UNICEF CHILDREN'S NET NEWS No.6
6 UNICEF CHILDREN'S NET NEWS No.6 1 NETWORKER s s 2 UNICEF CHILDREN'S NET NEWS No.6 a a a a a a a a a a a a UNICEF CHILDREN'S NET NEWS No.6 3 (%) 100 90 80 70 60 50 40 30 20 10 0 86 14 83 17 77 23 69 31
103 53 50 1975 541979 1992 59 1984 59 261951 37 37 3941 4648 501975 52 54 581983 60 57 57 57 57 57 57 104 105 541979 61 1990 1989 631988 56 57 52 58 56 61 551980 1990 5911 541979 461971 51 52 54 61 20
無印良品のスキンケア
2 3 4 5 P.22 P.10 P.18 P.14 P.24 Na 6 7 P.10 P.22 P.14 P.18 P.24 8 9 1701172 1,400 1701189 1,000 1081267 1,600 1701257 2,600 1125923 450 1081250 1,800 1125916 650 1081144 1,800 1081229 1,500 Na 1701240
1 Copyright 2009 INFOCOM CORPORATION All rights reserved.
/ 3.1 0 Copyright 2009 INFOCOM CORPORATION All rights reserved. 1 Copyright 2009 INFOCOM CORPORATION All rights reserved. H1N167 http://www-bm.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou04/ 2 Copyright
FDI2 22 BRICs 22 ODA 22 PF SSA FDI International Finance Corporation 29
1 21 198 1 1 OECD/DAC 22 28 27 29 ODA Remittance 12 1 1 199 25 FDI2 22 BRICs 22 ODA 22 PF 1 1 1 2 23 SSA 23 1 3 1 4 1 5 21 24 25 FDI 1999 22 1 6 25 27 25 International Finance Corporation 29 13 23 23 1
400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
MM0506-Ariyoshi.ind
51 2005133 Six years of experiences at the U.K. MRC Laboratories, The Gambia, in West Africa Koya ARIYOSHI 130 1965 1992 Jonathan Weber Medical Research Council MRC Laboratories, The Gambia HIV Virologist/Immunologist
1
1 1. 2 1-1. 2 3 1-2.2 4 2. 5 6 7 2-1 2-2 2-3 2-4 2-5 2-1 2-2 2-3 2-4 2-5 PDF PDF 8 P10 9 2-1. 10 2-1. 11 2-1. ( ( 12 2-1. 24 13 2-1. 3 3 14 2-1. 15 2-2. 16 17 2-2. 3 18 2-2. 19 2712 3 1000 20 2841 21 ...
untitled
-- -- -3- % % % 6% % % 9 66 95 96 35 9 6 6 9 9 5 77 6 6 5 3 9 5 9 9 55 6 5 9 5 59 () 3 5 6 7 5 7 5 5 6 6 7 77 69 39 3 6 3 7 % % % 6% % % (: ) 6 65 79 7 3 36 33 9 9 5 6 7 3 5 3 -- 3 5 6 76 7 77 3 9 6 5
untitled
NO. 2007 10 10 34 10 10 0570-058-669 http://www.i-nouryoku.com/index.html (40 ) () 1 NO. 2007 10 10 2.2 2.2 130 70 20 80 30 () () 9 10 () 78 8 9 () 2 NO. 2007 10 10 4 7 3 NO. 2007 10 10 40 20 50 2 4 NO.
17. (1) 18. (1) 19. (1) 20. (1) 21. (1) (3) 22. (1) (3) 23. (1) (3) (1) (3) 25. (1) (3) 26. (1) 27. (1) (3) 28. (1) 29. (1) 2
1. (1) 2. 2 (1) 4. (1) 5. (1) 6. (1) 7. (1) 8. (1) 9. (1) 10. (1) 11. (1) 12. (1) 13. (1) 14. (1) 15. (1) (3) 16. (1) 1 17. (1) 18. (1) 19. (1) 20. (1) 21. (1) (3) 22. (1) (3) 23. (1) (3) 24. 1 (1) (3)
BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI
20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old
第３章 焼却灰溶融システムの現状、焼却灰溶融スラグのリサイクルの動向・問題点
18 5 23 450 100~150 1300 1998 10 25 1 1 27 1819 60 3 300t 28.8t 2 62 118t16 12.3 16h 24 3 4 120t 9.6t24h 3 4 100t24h 15t24h 3 4 600t24h 500t24h 5 2 300t24h 75t24h 6 8 80 24h 9.6 24h 4 300t24h 52 24 11
4 13 STEP- 3 12
4 q STEP- 1? q P11 w P15 e P16 r P18 t P19 y P20 u P22 i P23 o P24!0 P26!1 P27!2 P28 STEP- 2 10 11 4 13 STEP- 3 12 4 w STEP- 1 STEP- 2 STEP- 3 14 15 4 e STEP- 1 STEP- 3 STEP-2 STEP- 2 16 17 4 r t STEP-
ほんぶん－第６章.indd
m,m ...,,,..... BCG - /.... T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S
野岩鉄道の旅
29th 5:13 5:34 5:56 6:00 6:12 6:20 6:21 6:25 6:29 6:31 6:34 6:38 6:40 6:45 6:52 6:56 7:01 7:07 7:11 7:32 7:34 7:50 7:58 8:03 8:17 8:36 8:44 5:50 5:54 6:15 6:38 6:39 6:51 6:59 6:59 7:03 7:08 7:08 7:11 7:15
VOL. 21 NO. 2 CHEMOTHERAPY 395
394 CHEMOTHERAPY MAR. 1973 VOL. 21 NO. 2 CHEMOTHERAPY 395 396 CHEMOTHERAPY MAR. 1973 VOL. 21 NO. 2 CHEMOTHERAPY 397 398 CHEMOTHERAPY MAR. 1973 VOL. 2 1 NO. 2 CHEMOTHERAPY 399 400 CHEMOTHERAPY MAR. 1973
評価結果報告書の概要版（平成20年度）
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76
sick contact1l
Clinical Question 2017 年 5 月 15 日 分野 : 内分泌テーマ : 治療 19 14 15 18 sick contact1l 170cm/68.8kg, GCSE1V1M5, HR: 120/min, BP: 104/60mmHg, RR: 30/min, SpO 2 : 96%, BT: 38.0 WBC Hb PLT CRP Cr BUN 23400 15.0 35.5
